SETH V. HETHERINGTON, M.D.

Dr. Hetherington joined Icagen in June 2006 as Senior

Vice President, Clinical and Regulatory Affairs.  Dr.

Hetherington's career in clinical drug development and

academic medicine spans a period of over twenty-five

years. From 2002 to May 2006, Dr. Hetherington served as

Vice President, Clinical Development and Chief Medical

Officer at Inhibitex, a biotechnology company. From 1995 to

2002, Dr. Hetherington served in positions of increasing

responsibility in clinical drug development at

GlaxoSmithKline and Glaxo Wellcome. During this period,

Dr. Hetherington made significant contributions to several clinical development programs, including work on the currently marketed pharmaceuticals Ziagen, Trizivir and Agenerase. During this period Dr. Hetherington also served as a faculty member at the University of North Carolina School of Medicine. Prior to joining Glaxo Wellcome, Dr. Hetherington held appointments at several leading academic medical centers, including the University of Tennessee, St. Jude Children's Research Hospital in Memphis and Albany Medical College. Dr Hetherington earned his B.S. at Yale University and his M.D. at the University of North Carolina, Chapel Hill. He completed his postgraduate training in pediatrics and pediatric infectious diseases at the University of North Carolina and the University of Minnesota, respectively. Dr. Hetherington currently serves as the industry representative to the Vaccines and Related Blood Products Advisory Committee of the FDA.  Dr. Hetherington has published extensively in the medical and scientific literature, and is board certified in both pediatrics and pediatric infectious diseases.